enGene Holdings Income Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Year Ending	TTM	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020
Selling, General & Admin	19.71	9.6	3.96	3.41	3.24
Research & Development	25.07	16.46	15.47	12.46	10.61
Operating Expenses	44.77	26.06	19.43	15.87	13.85
Operating Income	-44.77	-26.06	-19.43	-15.87	-13.85
Interest Expense	-3.89	-4.95	-1.42	-5.02	-3.7
Interest & Investment Income	4.81	1.12	0.13	0.03	0.06
Currency Exchange Gain (Loss)	-0.1	-0.1	-0.7	-0.1	-0.1
Other Non Operating Income (Expenses)	-9.28	-10.6	-3.02	-4.2	0.97
EBT Excluding Unusual Items	-53.24	-40.6	-24.44	-25.17	-16.63
Other Unusual Items	-59.67	-59.3	-	1.73	1.56
Pretax Income	-112.9	-99.9	-24.44	-23.44	-15.07
Income Tax Expense	0.01	0.02	0.02	-	-
Net Income	-112.91	-99.92	-24.46	-23.44	-15.07
Preferred Dividends & Other Adjustments	2.43	4.82	4.56	-1.19	1.58
Net Income to Common	-115.35	-104.74	-29.02	-22.25	-16.65
Shares Outstanding (Basic)	16	1	1	4	3
Shares Outstanding (Diluted)	16	1	1	4	3
Shares Change (YoY)	2333.89%	5.72%	-81.61%	28.93%	-
EPS (Basic)	-7.23	-151.22	-44.30	-6.25	-6.02
EPS (Diluted)	-7.23	-151.22	-44.30	-6.25	-6.02
Free Cash Flow	-36.59	-25.06	-17.75	-16.23	-13.25
Free Cash Flow Per Share	-2.29	-36.18	-27.09	-4.56	-4.80
EBITDA	-44.52	-25.89	-19.19	-15.6	-13.59
D&A For EBITDA	0.25	0.18	0.24	0.27	0.26
EBIT	-44.77	-26.06	-19.43	-15.87	-13.85

Source: S&P Capital IQ. Standard template.